Complaint
Ipratropium Bromide
Generic Name: Ipratropium Bromide
CAS: C20H30BrNO3
Indication: 1. For the relief of bronchospasm and wheezing symptoms caused by chronic obstructive pulmonary disease (COPD). 2. Prevention and treatment of asthma, especially for patients who cannot tolerate such drugs because of muscle tremor and tachycardia caused by β -receptor agonists
SSY Group Limited, established in 1948, principally specializes in R&D, manufacture, and sale of a widerange of pharmaceutical products, including various dosage forms such as intravenous injections, tablets, capsule, ampoules, APIs and medical packaging materials.The main subsidiaries of SSY are as follows
Shijiazhuang No 4 Pharmaceutical Co, Ltd
Hebei Guangxiang Pharmaceutical Co, Ltd.
Hebei Guolong Pharmaceutical Co, Ltd
Jiangsu Best New Medical Material Co, Ltd.
Hebei Hanlin Bio-tech Co., Ltd.
With more than 70-year development, our products
have been sold to both domestic and overseas markets up to more than 80 countries and regions.
Hebei Guangxiang Pharmaceutical Co., Ltd. is a super-large pharmaceutical enterprise, with 3 billion RMB investment and an area of 1000mu(equals to about 667,000m2) in the Biomedical Industrial Park of Cangzhou Bohai New Area. It seizes the timely opportunity of Beijing-Tianjin-Hebei integrated development and firmly relies on the abundant capital, R&D strength and brand influence of SSY Group. Concentrating on API, intermediate compounds and bio-pharmaceutical preparations, its main products are API series products, metronidazole, nifedipine, theophylline, aminophylline, azithromycin, abidol and other series of products and biomedical preparations.
The manufacturing of main products among them- API series products replaces traditional intermittent production into intelligent continuous production with advanced process equipment, automation and information technology, greatly improving production efficiency.
